Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.
Ontology highlight
ABSTRACT: Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3, the most common dominant spinocerebellar ataxia (SCA) worldwide, is caused by over-repetition of a CAG repeat in the ATXN3/MJD1 gene, which translates into a polyglutamine tract within the ataxin-3 protein. There is no treatment for this fatal disorder. Despite evidence of the safety and efficacy of mesenchymal stromal cells (MSCs) in delaying SCA disease progression in exploratory clinical trials, unanticipated regression of patients to the status prior to treatment makes the investigation of causes and solutions urgent and imperative. In the present study, we compared the efficacy of a single intracranial injection with repeated systemic MSC administration in alleviating the MJD phenotype of two strongly severe genetic rodent
SUBMITTER: Oliveira Miranda C
PROVIDER: S-EPMC6127516 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA